Addressing a different cancer pathway, the catalytic mTOR/PI3K inhibitor BEZ-235 was seen to display strong synergy with the non-catalytic mTOR inhibitor rapamycin – an outcome that is strongly mechanistically supported in a recent publication showing that rapalogues and catalytic mTORC inhibitors can suppress mTOR activity synergistically [13]. Here, MTOR is linked to cancer.